Advocates Cheer FDA Review of Abortion Pill Restrictions

“The evidence is crystal clear: Mifepristone is safe and effective, and the FDA’s unique restrictions provide no safety benefit while severely burdening patient’s ability to access care. … If the FDA follows the science, we should soon see the removal of these barriers to care.”

—Julia Kaye, staff attorney at ACLU’s Reproductive Freedom Project

‍

On Friday, May 7, the Biden administration announced that the U.S. Food and Drug Administration (FDA) will undertake a review of longstanding restrictions on the medication mifepristone used for miscarriage and abortion care. The announcement came as part of a joint legal filing in the ACLU lawsuit Cheslius v. Becerra, challenging the restrictions.

Read the full article here.

Advocates Cheer FDA Review of Abortion Pill Restrictions

“The evidence is crystal clear: Mifepristone is safe and effective, and the FDA’s unique restrictions provide no safety benefit while severely burdening patient’s ability to access care. … If the FDA follows the science, we should soon see the removal of these barriers to care.”

—Julia Kaye, staff attorney at ACLU’s Reproductive Freedom Project

Go back

Read the full article